ALX Oncology Holdings Inc
ALXO
查看详细走势图
2.050USD
-0.010-0.49%
收盘 02/06, 16:00（美东）报价延迟15分钟
109.83M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-0.49%
5天
+17.82%
1月
+89.81%
6月
+192.44%
今年开始到现在
+81.42%
1年
+70.83%
查看详细走势图
TradingKey ALX Oncology Holdings Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
ALX Oncology Holdings Inc当前公司基本面数据相对谨慎，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名58/392位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价3.33。中期看，股价处于上升通道。近一个月，市场表现很强，技术面评分较高，但很强的走势得没有得到基本面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
ALX Oncology Holdings Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看空
ALX Oncology Holdings Inc亮点
亮点风险
ALX Oncology Holdings Inc. is a clinical-stage biotechnology company advancing a pipeline of therapies designed to treat cancer and extend patients’ lives. The Company's lead product candidate, evorpacept, is a CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. It is engaged in focusing on combining evorpacept with anti-cancer antibodies, antibody drug conjugate (ADCs), and PD-1/PD-L1 immune checkpoint inhibitors. Evorpacept is being evaluated across multiple ongoing clinical trials in a range of cancer indications. Its second product candidate is ALX2004, an epidermal growth factor receptor (EGFR)-targeted ADC. ALX2004 comprises an affinity-tuned EGFR antibody backbone engineered for optimal activity as an ADC, a proprietary topoisomerase I inhibitor payload with enhanced bystander effect, and a linker with enhanced stability.
估值合理
公司最新PE估值-1.02，处于3年历史合理位
机构加仓
最新机构持股35.78M股，环比增加1.57%
詹姆斯·西蒙斯持仓
明星投资者詹姆斯·西蒙斯持仓，最新持仓市值164.50K
活跃度增加
近期活跃度增加，过去20天平均换手率0.59
分析师目标
根据
5
位分析师
买入
评级
3.333
目标均价
+61.81%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
ALX Oncology Holdings Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
ALX Oncology Holdings Inc简介
ALX Oncology Holdings Inc. is a clinical-stage biotechnology company advancing a pipeline of therapies designed to treat cancer and extend patients’ lives. The Company's lead product candidate, evorpacept, is a CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. It is engaged in focusing on combining evorpacept with anti-cancer antibodies, antibody drug conjugate (ADCs), and PD-1/PD-L1 immune checkpoint inhibitors. Evorpacept is being evaluated across multiple ongoing clinical trials in a range of cancer indications. Its second product candidate is ALX2004, an epidermal growth factor receptor (EGFR)-targeted ADC. ALX2004 comprises an affinity-tuned EGFR antibody backbone engineered for optimal activity as an ADC, a proprietary topoisomerase I inhibitor payload with enhanced bystander effect, and a linker with enhanced stability.
公司代码ALXO
公司ALX Oncology Holdings Inc
CEOLettmann (Jason)
网址https://alxoncology.com/
相关品种
